View printer-friendly version
« Back
February 14, 2000 3:19 p.m.
Teva Pharmaceutical Industries Ltd. Declares Regular Quarterly Cash Dividend and Announces a Two for One Stock Split

Jerusalem, Israel, February 14, 2000 - . Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Teva's Board of Directors approved the fourth quarter dividend amounting to approximately $6.8 million, (based on current exchange rates), which reflects a 57% increase and equals approximately $0.11 per pre-split ADR. The shareholder record date for the cash dividend is February 21, 2000, and will be payable on March 15, 2000. The expected rate of income tax to be withheld at source is 25%.

In addition, Teva's Board of Directors has approved a two for one stock split of the Company's Ordinary Shares, which will be effected in the form of a 100% stock dividend. Each ADR will entitle its holder to one additional ADR. Shareholders of record at the close of business February 22, 2000, will receive one additional Ordinary Share (or ADR) for each Ordinary (or ADR) held. Certificates for the additional shares and/or ADRs will be distributed by the Company's transfer agent on or about March 24, 2000. Based on the number of shares currently outstanding, following the effective date of the split, Teva will have approximately 126 million Ordinary Shares outstanding.

Teva Pharmaceutical Industries Ltd. is Israel's largest pharmaceutical company, with over 80% of its sales outside Israel, mainly in the United States and Europe. The Company develops, manufactures and markets generic and branded human pharmaceuticals, active pharmaceutical ingredients and medical disposables.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration ("FDA") and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission ("SEC"). Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.